- Home
- NRDS vs TSHA Comparison
NRDS vs TSHA Comparison
Compare NRDS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- TSHA
- Stock Information
- Founded
- NRDS 2009
- TSHA 2019
- Country
- NRDS United States
- TSHA United States
- Employees
- NRDS N/A
- TSHA N/A
- Industry
- NRDS EDP Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NRDS Technology
- TSHA Health Care
- Exchange
- NRDS Nasdaq
- TSHA Nasdaq
- Market Cap
- NRDS 810.0M
- TSHA 728.4M
- IPO Year
- NRDS 2021
- TSHA 2020
- Fundamental
- Price
- NRDS $10.59
- TSHA $2.68
- Analyst Decision
- NRDS Buy
- TSHA Strong Buy
- Analyst Count
- NRDS 6
- TSHA 6
- Target Price
- NRDS $15.17
- TSHA $8.17
- AVG Volume (30 Days)
- NRDS 417.1K
- TSHA 2.9M
- Earning Date
- NRDS 07-30-2025
- TSHA 08-11-2025
- Dividend Yield
- NRDS N/A
- TSHA N/A
- EPS Growth
- NRDS N/A
- TSHA N/A
- EPS
- NRDS 0.38
- TSHA N/A
- Revenue
- NRDS $734,900,000.00
- TSHA $7,224,000.00
- Revenue This Year
- NRDS $18.07
- TSHA N/A
- Revenue Next Year
- NRDS $8.22
- TSHA N/A
- P/E Ratio
- NRDS $28.05
- TSHA N/A
- Revenue Growth
- NRDS 24.20
- TSHA N/A
- 52 Week Low
- NRDS $7.55
- TSHA $1.05
- 52 Week High
- NRDS $16.45
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- NRDS 42.52
- TSHA 59.68
- Support Level
- NRDS $11.07
- TSHA $2.33
- Resistance Level
- NRDS $11.49
- TSHA $2.51
- Average True Range (ATR)
- NRDS 0.32
- TSHA 0.14
- MACD
- NRDS -0.04
- TSHA 0.02
- Stochastic Oscillator
- NRDS 13.19
- TSHA 90.43
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.